MedTrace Logo

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

NCT00385125 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-10-06

No results posted yet for this study

Summary

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

Conditions

  • Lymphoma, High-Grade

Interventions

DRUG

Bendamustine

DRUG

Rituximab

Sponsors & Collaborators

  • University of Magdeburg

    lead OTHER

Principal Investigators

  • Martin Mohren, PD · University of Magdeburg, Department of Hematology and Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385125 on ClinicalTrials.gov